3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Letrozole
23
Docetaxel
17
Cyclophosphamide
13
Zoledronic Acid
12
Trastuzumab
12
Anastrozole
12
exemestane
11
Tamoxifen
11
Paclitaxel
11
Capecitabine
10
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
Saline Solution
7
Bupivacaine
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Sodium Chloride
6
Filgrastim
6
Carboplatin
6
pegylated granulocyte colony-stimulating factor
5
palbociclib
5
Ropivacaine
5
Dexmedetomidine
5
Bevacizumab
5
ribociclib
4
eribulin
4
Vinorelbine
4
Tranexamic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
gadoterate meglumine
×
Breast
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled